Monographie - Propofol - Stabilis 4.0

Laatste update :
19/11/2024

Propofol

Molecuulstructuur

Merknamen in verschillende landen

Handelsnamen zijn slechts een indicatie; de samenstelling van hulpstoffen kan per land variëren afhankelijk van de fabrikant

Abbofol	Polen
Anesia	Duitsland
Diprivan	Argentinië, Australië, Canada, Chili, Colombia, Denemarken, Egypte, Finland, Frankrijk, Groot Britannië, Hongarije, Ierland, Iran, Italië, Luxemburg, Marokko, Mexico, Nederland, nieuw Zeeland, Oostenrijk, Peru, Polen, Portugal, Saudi-Arabië, Spanje, Tunisie, Turkije, USA, Venezuela, Zweden
Diprofol	Ierland
Disoprivan	Duitsland, Zwitserland
Fresofol	Argentinië, Colombia, Indië, Maleisië, Mexico, nieuw Zeeland
Gobbifol	Argentinië
Indufol	Colombia
Plofed	Polen
Pofol	Turkije
Propolipid	Duitsland, Noorwegen, Zweden
Propovan	Argentinië
Recofol	Egypte, Finland, Iran, Saudi-Arabië, Spanje, Verenigde Arabische Emiraten
Troypofol	Colombia, Verenigde Arabische Emiraten

Literatuur : Propofol

	type	publicatie
125	Artikel	Chernin EL, Stewart JT, Smiler B. Stability of thiopental sodium and propofol in polypropylene syringes at 23 and 4°C. Am J Health-Syst Pharm 1996 ; 53: 1576-1579.
126	Artikel	Prankerd RJ, Jones RD. Physicochemical compatibility of propofol with thiopental sodium. Am J Health-Syst Pharm 1996 ; 53: 2606-2610.
300	Artikel	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
309	Artikel	Bhatt-Mehta V, Paglia RE, Rosen DA. Stability of propofol with parenteral nutrient solutions during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 192-196.
319	Artikel	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
347	Artikel	Bailey LC, Tang KT, Rogozinski BA. Effect of syringe filter and IV administration set on delivery of propofol emulsion. Am J Hosp Pharm 1991 ; 48: 2627-2630.
660	Artikel	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
794	Artikel	Lilley EMM, Isert PR, Carasso ML, Kennedy RA. The effect of the addition of lignocaine on propofol emulsion stability. Anaesthesia 1996 ; 51: 815-818.
813	Artikel	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
815	Artikel	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
919	Artikel	Lazar ER, Jolly DT, Tam YK, Hrazdil J, Tawfik SR, Clanachan AS. Propofol and thiopental in a 1:1 volume mixture is chemically stable. Anesth Analg 1998 ; 86: 422-426.
1508	Artikel	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1672	Artikel	Lamontagne C, Brouillette D, Hardy JF. Incompatibility of propofol emulsion with anesthesic drugs. Anesthesiology 1998 ; 89: 1609.
1712	Artikel	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1759	Artikel	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1803	Artikel	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1860	Artikel	Sautou-Miranda V, Levadoux E, Groueix MT, Chopineau J. Compatibility of propofol diluted in 5% glucose with glass and plastics (polypropylene, molyvinylchloride) containers. Int J Pharm 1996 ; 130: 251-255.
1861	Artikel	Levadoux E, Sautou V, Bazin JE, Schoeffler P, Chopineau J. Medical plastics: compatibility of alfentanil and propofol alone or mixed. Stability of the alfentanil-propofol mixture. Int J Pharm 1996 ; 127: 255-259.
1863	Artikel	Isert PR, Lee D, Naidoo D, Carasso ML, Kennedy RA. Compatibility of propofol, fentanyl,and vecuronium mixtures designed for potential use in anesthesia and patient transport. Journal of clinical anesthesia 1996 ; 8: 329-336.
2053	Artikel	Masaki Y, Tanaka M, Nishikawa T. Physicochemical compatibility of propofol-lidocaine mixture. Anesth Analg 2003 ; 97: 1646-1651.
2078	Artikel	Loff S, Kabs F, Witt K, Sartoris J, Mandl B, Niessen KH, Waag KL. Polyvinylchloride infusion lines expose infants to large amounts of toxic plasticizers. J Ped Surg 2000 ; 35: 1775-1781.
2141	Artikel	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Artikel	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2262	Artikel	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Artikel	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2312	Artikel	Trissel L.A, Trusley C, Kupiec T.C, Ben M. Compatibility and stability of palonosetron hydrochloride and propofol during simulated Y-site administration. Int J Pharm Compound 2009 ; 13, 1: 78-80.
2325	Artikel	Nemec K, Germ E, Schulz-Siegmund M, Ortner A. The effect of nimodipine, fentanyl and remifentanil intravenous products on the stability of propofol emulsions. Pharmazie 2009 ; 64, 2: 94-97.
2329	Artikel	Donnely R.F, Willman E, Andolfatto G. Stability of Ketamine-Propofol mixtures for procedural sedation and analgesia in the emergency department. Can J Hosp Pharm 2008 ; 61, 6: 426-430.
3176	Poster	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3249	Artikel	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Artikel	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3294	Artikel	Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs EJHP 2012 ; 19: 57-64.
3332	fabrikant	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3385	Artikel	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3502	fabrikant	Propofol (Diprivan®) - Summary of Products Characteristics Astra Zeneca 2012
3519	fabrikant	Remifentanil hydrochloride(Ultiva®) - Summary of Product Characteristics Glaxo Smith Kline 2011
3601	fabrikant	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
3659	fabrikant	Propofol (Diprivan®) - Résumé des caractéristiques du produit AstraZeneca 2016
3781	Artikel	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	fabrikant	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
4011	Artikel	Gersonde F, Eisend S, Haake N, Kunze T. Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. EJHP 2016 2016;0:1-11
4055	Artikel	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4080	Artikel	Zbytovska J, Gallusova J, Vidlarova L, Prochazkova K, Simek J, Stepanek F. Physical Compatibility of Propofol-Sufentanil Mixtures. Anaesthesia 2017 ;124,3:776-781
4145	Artikel	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4157	Artikel	Izgi M, Basara B, Muderrisoglu A, Yilbas A.A, Uluer M.S, Celebioglu B. Evaluation of the stability and stratification of propofol and ketamine mixtures for pediatric anesthesia. Pediatric Anesthesia 2018
4331	Artikel	Nilsson N, Nezvalova-Henriksen K, Tho I. Emulsion Stability of Different Intravenous Propofol Formulations in Simulated Co-Administration with Remifentanil Hydrochloride. Pharmaceutical Technology in Hospital Pharmacy 2019
4433	Artikel	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Artikel	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4435	Artikel	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4470	Artikel	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4501	Artikel	Henkel E, Vella R, Behan K, Austin D, Kruger P, Fenning A. The effect of concentration, reconstitution solution and pH on the stability of a remifentanil hydrochloride and propofol admixture for simultaneous co-infusion. BMC Anesthesiology 2020 ;20:283.
4524	Poster	Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009
4528	Artikel	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4569	Artikel	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4603	Artikel	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4801	Artikel	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales